scholarly journals Oral Vaccine Delivery for Intestinal Immunity—Biological Basis, Barriers, Delivery System, and M Cell Targeting

Polymers ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 948 ◽  
Author(s):  
Sung Kang ◽  
Seok Hong ◽  
Yong-Kyu Lee ◽  
Sungpil Cho
Keyword(s):  
Immune Response ◽  
Vaccine Development ◽  
Oral Vaccine ◽  
Vaccine Delivery ◽  
Mucosal Immune Response ◽  
Delivery Systems ◽  
Intestinal Immunity ◽  
M Cell ◽  
Systemic Injection ◽  
Biological Basis

Most currently available commercial vaccines are delivered by systemic injection. However, needle-free oral vaccine delivery is currently of great interest for several reasons, including the ability to elicit mucosal immune responses, ease of administration, and the relatively improved safety. This review summarizes the biological basis, various physiological and immunological barriers, current delivery systems with delivery criteria, and suggestions for strategies to enhance the delivery of oral vaccines. In oral vaccine delivery, basic requirements are the protection of antigens from the GI environment, targeting of M cells and activation of the innate immune response. Approaches to address these requirements aim to provide new vaccines and delivery systems that mimic the pathogen’s properties, which are capable of eliciting a protective mucosal immune response and a systemic immune response and that make an impact on current oral vaccine development.

scholarly journals Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines

2019 ◽  
Vol 2019 ◽  
pp. 1-13 ◽  
Author(s):  
E. Criscuolo ◽  
V. Caputo ◽  
R. A. Diotti ◽  
G. A. Sautto ◽  
G. A. Kirchenbaum ◽  
...  
Keyword(s):  
Immune Response ◽  
Vaccine Delivery ◽  
Mucosal Immune Response ◽  
Delivery Systems ◽  
Cold Chain ◽  
Alternative Methods ◽  
Self Administration ◽  
Molecular Features ◽  
Cell Mediated Immune Response ◽  
Intradermal Vaccine

Vaccines are recognized worldwide as one of the most important tools for combating infectious diseases. Despite the tremendous value conferred by currently available vaccines toward public health, the implementation of additional vaccine platforms is also of key importance. In fact, currently available vaccines possess shortcomings, such as inefficient triggering of a cell-mediated immune response and the lack of protective mucosal immunity. In this regard, recent work has been focused on vaccine delivery systems, as an alternative to injectable vaccines, to increase antigen stability and improve overall immunogenicity. In particular, novel strategies based on edible or intradermal vaccine formulations have been demonstrated to trigger both a systemic and mucosal immune response. These novel vaccination delivery systems offer several advantages over the injectable preparations including self-administration, reduced cost, stability, and elimination of a cold chain. In this review, the latest findings and accomplishments regarding edible and intradermal vaccines are described in the context of the system used for immunogen expression, their molecular features and capacity to induce a protective systemic and mucosal response.

M-cell Targeting Acid-resistant Oral Vaccine Delivery for Immunization Against Hepatitis B Infection Using Cationic Solid Lipid Nanoparticles

2021 ◽  
Author(s):  
Surendra Saraf ◽  
Rudra Narayan Sahoo ◽  
Shailesh Jain ◽  
Subrata Mallick
Keyword(s):  
Hepatitis B ◽  
Solid Lipid Nanoparticles ◽  
Oral Vaccine ◽  
Vaccine Delivery ◽  
Lipid Nanoparticles ◽  
Hepatitis B Infection ◽  
Cell Targeting ◽  
M Cell ◽  
Promising Alternative ◽  
Solid Lipid

Abstract Background: Viral infection caused by Hepatitis B is transmitted by permucosal or parenteral exposure and also one of the prime causes of hepatocellular carcinoma and liver cirrhosis. Objectives: M-cell targeting acid-resistant oral vaccine delivery have been formulated for immunization against Hepatitis B infection. Methods: Cationic solid lipid nanoparticles (cSLNs) were prepared utilizing solvent injection technique. Hepatitis B surface antigen (HBsAg) loaded alginate coated cSLNs were anchored with lipopolysaccharide (LPS). SDS-PAGE was performed to evaluate acid degradation protection of prepared formulation. Induction of immunity produced by prepared nanoparticle for Hepatitis B was determined on female Balb/c mice followed by ELISA assays for assessing anti-HBsAg IgG/IgA antibodies in mucosal fluids. Results: Sustained release of HBsAg (60.66 %) has been exhibited from alginate coated cSLNs in comparison to cSLNs without alginate coating (97.72 %) after 48 h. The production of anti-HBs titer in intestinal, salivary and vaginal secretions was 3.41 IU/ml, 3.1 IU/ml and 2.51 IU/ml respectively in comparison to the control group. Integrity of the M-cells has been maintained after binding with SLN, and oral administration delivered the antigen to the desired site of gut. Conclusion: It was found effective in producing antibodies in mucosal immunization against Hepatitis B virus. So, this formulation could be used as a promising alternative preexisting vaccine to prevent Hepatitis B infection.

Complexation hydrogels as potential carriers in oral vaccine delivery systems

2017 ◽  
Vol 112 ◽  
pp. 138-142 ◽  
Author(s):  
Mia Yoshida ◽  
Noriyasu Kamei ◽  
Keiya Muto ◽  
Jun Kunisawa ◽  
Kozo Takayama ◽  
...  
Keyword(s):  
Oral Vaccine ◽  
Vaccine Delivery ◽  
Delivery Systems

scholarly journals Expression of a Functional Single-Chain Variable-Fragment Antibody against Complement Receptor 1 in Streptococcus gordonii

2008 ◽  
Vol 15 (6) ◽  
pp. 925-931 ◽  
Author(s):  
Jennifer B. Knight ◽  
Scott A. Halperin ◽  
Kenneth A. West ◽  
Song F. Lee
Keyword(s):  
Immune Response ◽  
Dendritic Cells ◽  
Vaccine Development ◽  
Oral Vaccine ◽  
Complement Receptor ◽  
Streptococcus Gordonii ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
Complement Receptor 1

ABSTRACT Streptococcus gordonii, an oral commensal organism, is a candidate vector for oral-vaccine development. Previous studies have shown that recombinant S. gordonii expressing heterologous antigens was weakly immunogenic when delivered intranasally. In this study, antigen was specifically targeted to antigen-presenting cells (APC) in order to potentiate antigen-APC interactions and increase the humoral immune response to the antigen. To achieve this goal, a single-chain variable-fragment (scFv) antibody against complement receptor 1 (CR1) was constructed. Anti-CR1 scFv purified from Escherichia coli was able to bind to mouse mixed lymphocytes and bone marrow-derived dendritic cells. The in vivo function of the anti-CR1 scFv protein was assessed by immunizing mice intranasally with soluble scFv and determining the immune response against the hemagglutinin (HA) peptide located on the carboxy terminus of the scFv. The serum anti-HA immunoglobulin G (IgG) immune response was dose dependent; as little as 100 ng of anti-CR1 scFv induced a significant IgG immune response, while such a response was minimal when the animals were given an unrelated scFv. The anti-CR1 scFv was expressed in S. gordonii as a secreted protein, which was functional, as it bound to dendritic cells. Mice orally colonized by the anti-CR1-secreting S. gordonii produced an anti-HA IgG immune response, indicating that such an approach can be used to increase the immune response to antigens produced by this bacterium.

scholarly journals An Overview on the Field of Micro- and Nanotechnologies for Synthetic Peptide-Based Vaccines

2011 ◽  
Vol 2011 ◽  
pp. 1-18 ◽  
Author(s):  
Aiala Salvador ◽  
Manoli Igartua ◽  
Rosa Maria Hernández ◽  
José Luis Pedraz
Keyword(s):  
Immune Response ◽  
Immune System ◽  
Innate Immune System ◽  
Synthetic Peptide ◽  
Vaccine Delivery ◽  
Delivery Systems ◽  
Innate Immune ◽  
Cross Presentation ◽  
Antigen Presenting

The development of synthetic peptide-based vaccines has many advantages in comparison with vaccines based on live attenuated organisms, inactivated or killed organism, or toxins. Peptide-based vaccines cannot revert to a virulent form, allow a better conservation, and are produced more easily and safely. However, they generate a weaker immune response than other vaccines, and the inclusion of adjuvants and/or the use of vaccine delivery systems is almost always needed. Among vaccine delivery systems, micro- and nanoparticulated ones are attractive, because their particulate nature can increase cross-presentation of the peptide. In addition, they can be passively or actively targeted to antigen presenting cells. Furthermore, particulate adjuvants are able to directly activate innate immune system in vivo. Here, we summarize micro- and nanoparticulated vaccine delivery systems used in the field of synthetic peptide-based vaccines as well as strategies to increase their immunogenicity.

scholarly journals The Potential of Calcium Phosphate Nanoparticles as Adjuvants and Vaccine Delivery Vehicles

2021 ◽  
Vol 8 ◽  
Author(s):  
Zhe Sun ◽  
Wenyi Li ◽  
Jason C. Lenzo ◽  
James A. Holden ◽  
Michael J. McCullough ◽  
...  
Keyword(s):  
Immune Response ◽  
Calcium Phosphate ◽  
Vaccine Development ◽  
Vaccine Delivery ◽  
Vaccine Design ◽  
Cost Effective ◽  
Research Groups ◽  
Immunological Effects ◽  
Calcium Phosphate Nanoparticles ◽  
Delivery Vehicles

Vaccination is one of the most efficacious and cost-effective ways to protect people from infectious diseases and potentially cancer. The shift in vaccine design from disrupted whole pathogens to subunit antigens has brought attention on to vaccine delivery materials. For the last two decades, nanotechnology-based vaccines have attracted considerable attention as delivery vehicles and adjuvants to enhance immunogenicity, exemplified with the current COVID vaccines. The nanoparticle vaccines display unique features in protecting antigens from degradation, controlled antigen release and longer persisting immune response. Due to their size, shape and surface charge, they can be outstanding adjuvants to achieve various immunological effects. With the safety and biodegradable benefit of calcium phosphate nanoparticles (CaP NPs), they are an efficient carrier for vaccine design and adjuvants. Several research groups have studied CaP NPs in the field of vaccination with great advances. Although there are several reports on the overview of CaP NPs, they are limited to the application in biomedicine, drug delivery, bone regeneration and the methodologies of CaP NPs synthesis. Hence, we summarised the basic properties of CaP NPs and the recent vaccine development of CaP NPs in this review.

Sign in / Sign up

Export Citation Format

Share Document